Clinical Trial Update: (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). [Phase 1]

View source ↗

Summary

Phase 1 pediatric lymphoma trial evaluating pediTACTAL TAA-specific cytotoxic T-lymphocytes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• pediTACTAL (TAA-specific cytotoxic T-lymphocytes)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hodgkins Lymphoma, Non Hodgkins Lymphoma | Phase 1 | Status: WITHDRAWN